Survival of endometrial cancer patients in Germany in the early 21st century: A period analysis by age, histology, and stage

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Chen, Tianhui ^a,b,f   Jansen, Lina ^b   Gondos, Adam ^b   Ressing, Meike ^c   Holleczek, Bernd ^d   Katalinic, Alexander ^e   Brenner, Hermann ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d SAARLAND CANCER REGISTRY   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

^f ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer registries; Endometrial cancer; Germany; Period analysis; Population based; Survival

Indexed keywords

AGE; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CANCER; ENDOMETRIUM SARCOMA; GERMANY; HISTOLOGY; HUMAN; POPULATION RESEARCH; SQUAMOUS CELL METAPLASIA; SURVIVAL PREDICTION; TREND STUDY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; SURVIVAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REGISTRIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84859063311     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-128     Document Type: Article

References (57)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-917. 10.1002/ijc.25516, 21351269.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer: IARC CancerBase No. 10. 2010,
3. Averette HE, Steren A, Nguyen HN. Screening in gynecologic cancers. Cancer 1993, 72(3 Suppl):1043-9.
4. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005, 14:1132-42. 10.1158/1055-9965.EPI-04-0871, 15894663.
5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002, 11:1531-43.
6. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009, 45:931-91. 10.1016/j.ejca.2008.11.018, 19171476.
7. Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 2007, 25:3274-80. 10.1200/JCO.2007.11.3431, 17664474.
8. Kosary CL, , et al. Cancer of the corpus uteri SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics 2007, 123-32. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub, Gloeckler RLA, Young JL, Keel GE, Cancer of the corpus uteri.
9. Gloeckler RLA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541-52. 10.1634/theoncologist.8-6-541, 14657533.
10. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94:642-6. 2361201, 16495918.
11. Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 2005, 16:981-6. 10.1093/annonc/mdi186, 15849221.
12. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996, 78:2004-10. 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#, 8909323.
13. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004, 40:326-35. 10.1016/j.ejca.2003.10.013, 14746849.
14. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006, 164:689-96. 10.1093/aje/kwj243, 16840519.
15. Gondos A, Bray F, Brewster DH, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer 2008, 44:1463-75. 10.1016/j.ejca.2008.03.010, 18455387.
16. Hiripi E, Gondos A, Emrich K, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol 201 2012, 23:472-9.
17. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology 2000, Geneva: World Health Organization, 3.
18. Berrino F, Brown C, Moeller T. Sobin L 2002, ENCR Recommendations: Condensed TNM for Coding the Extent of Disease.
19. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002, 31:456-62. 10.1093/ije/31.2.456, 11980816.
20. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002, 20:826-32. 10.1200/JCO.20.3.826, 11821467.
21. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-21.
22. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations 1959, Bethesda (MD): National Cancer Institute.
23. Perme MP, Stare J, Estève J. On Estimation in Relative Survival. Biometrics doi: 10.1111/j.1541-0420.2011.01640.x.
24. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004, 40:2307-16. 10.1016/j.ejca.2004.07.002, 15454257.
25. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer 2002, 38:690-5. 10.1016/S0959-8049(02)00003-5, 11916552.
26. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8:784-96. 10.1016/S1470-2045(07)70246-2, 17714993.
27. Klint A, Tryggvadottir L, Bray F, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010, 49:632-43. 10.3109/02841861003691945, 20307243.
28. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009, 45:1042-66. 10.1016/j.ejca.2008.11.029, 19124239.
29. Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. Eur J Cancer 1998, 34:2218-25. 10.1016/S0959-8049(98)00326-8, 10070290.
30. Levi F, Randimbison L, La Vecchia C. Trends in endometrial cancer incidence and survival in the Swiss Canton of Vaud. Br J Cancer 1992, 66:720-2. 10.1038/bjc.1992.345, 1977421, 1419614.
31. Osmers RG, Osmers M, Kuhn W. Prognostic value of transvaginal sonography in asymptomatic endometrial cancers. Ultrasound Obstet Gynecol 1995, 6:103-7. 10.1046/j.1469-0705.1995.06020103.x, 8535911.
32. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001, 51:38-75. 10.3322/canjclin.51.1.38, 11577479.
33. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011, 61:8-30. 10.3322/caac.20096, 21205832.
34. Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol 2001, 184:70-5. 10.1067/mob.2001.111088, 11174482.
35. Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011, 12:38-48. 10.1016/S1470-2045(10)70268-0, 21147030.
36. Lin JF, Slomovitz BM. Uterine sarcoma 2008. Curr Oncol Rep 2008, 10:512-8. 10.1007/s11912-008-0077-9, 18928666.
37. Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008, 110:43-8. 10.1016/j.ygyno.2008.02.026, 18445505.
38. Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011,
39. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008, 198:218-6.
40. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009, 45:1006-16. 10.1016/j.ejca.2008.11.028, 19121578.
41. Gondos A, Holleczek B, Arndt V, et al. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?. Ann Oncol 2007, 18:1253-9. 10.1093/annonc/mdm126, 17470450.
42. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, 10:31-46. 10.1002/ssu.2980100107, 8115784.
43. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000, 36:1741-54. 10.1016/S0959-8049(00)00169-6, 10974621.
44. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997, 33:907-11. 10.1016/S0959-8049(97)00040-3, 9291814.
45. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001, 943:296-315.
46. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008, 15:485-97. 10.1677/ERC-07-0064, 2396334, 18509001.
47. Mylonas I, Jeschke U, Shabani N, et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 2007, 22:169-76.
48. Snijders MP, de Goeij AF, Debets-Te Baerts MJ, et al. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 1992, 94:363-71. 10.1530/jrf.0.0940363, 1593539.
49. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43:2434-44. 10.1016/j.ejca.2007.08.014, 17911007.
50. Jongen V, Briët J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009, 112:537-42. 10.1016/j.ygyno.2008.10.032, 19108875.
51. Miyamoto T, Watanabe J, Hata H, et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol 2004, 92:111-8. 10.1016/j.jsbmb.2004.07.007, 15555905.
52. Mylonas I. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep 2010, 24:385-93.
53. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol 2008, 67:204-12. 10.1016/j.critrevonc.2008.02.011, 18407513.
54. Osmers R, Volksen M, Schauer A. Vaginosonography for early detection of endometrial carcinoma?. Lancet 1990, 335:1569-71. 10.1016/0140-6736(90)91387-P, 1972495.
55. Tangjitgamol S, Anderson BO, See HT, et al. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1119-27. 10.1016/S1470-2045(09)70290-6, 19880066.
56. Chan JK, Sherman AE, Kapp DS, et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011, 29:832-8. 10.1200/JCO.2010.31.2124, 21263082.
57. Roland PY, Kelly FJ, Kulwicki CY, et al. The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. Gynecol Oncol 2004, 93:125-30. 10.1016/j.ygyno.2003.12.018, 15047225.